Abstract || Clinical Case Reports International

Major Scope

Cardiovascular Case Reports
Oncology Case Reports
Surgical Case Reports
Gastroenterological Case Reports
Neurological Case Reports
Dermatological Case Reports
Respiratory Case Reports
Obstetrics/Gynecology Case Reports
Nephrology Case Reports
Immunology Case Reports
Paediatric Case Reports
Orthopedics Case Reports
Dental Case Reports

Abstract

Citation: Clin Case Rep Int. 2023;7(1):1474.DOI: 10.25107/2638-4558.1474

Vedolizumab Like Biological First Choice for Chronic Refractory Pouchitis in Patients with Ulcerative Colitis

Vincenzo T and Annamaria D

Department of Medical and Surgical Sciences, University “Magna Graecia” of Catanzaro, Italy

^*Correspondance to: Trapanese Vincenzo

PDF Full Text Case Report | Open Access

Abstract:

Chronic Antibiotic-Refractory Pouchitis (CARP) is a complication of Ileal Pouch-Anal Anastomosis (IPAA), which poses a therapeutic challenge. Vedolizumab, a gut-selective monoclonal antibody to the α4β7 of integrin, has been used in such patients, but data on its efficacy are limited. Our case suggests the efficacy and safety of vedolizumab as induction therapy in CARP patient without a previous experience with anti-TNF agents. Larger studies with a higher number of patients are required to confirm these findings.

Keywords:

Vedolizumab; Chronic antibiotic-refractory puchitits; Ulcerative Colitis

Cite the Article:

Vincenzo T, Annamaria D. Vedolizumab Like Biological First Choice for Chronic Refractory Pouchitis in Patients with Ulcerative Colitis. Clin Case Rep Int. 2023; 7: 1474..